Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors

In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given.

Bolt Biotherapeutics is developing drugs intended to turn cold tumors—the majority of cancers—“hot” so that other immunotherapies can work, and has raised $54 million to support its research. The Redwood City, CA, startup says its goal is to unleash the immune system in patients for whom a class of cancer immunotherapies, called checkpoint inhibitors, are ineffective. Bolt Bio says it is now working toward human tests of its lead drug.

Bolt Bio’s approach gives a one-two punch to cancer…. Read more »





READ  App helps breast cancer survivors improve health after treatment

Leave a Reply